General
Preferred name
bosutinib
Synonyms
SKI-606 ()
Bosulif, SKI-606, Bosutinib Monohydrate ()
Bosutinib (SKI-606) ()
SKI 606 ()
PZ0192 ()
B18771 ()
4-(2,4-Dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile ()
Bosutinib (hydrate) ()
BOSULIF ()
BOSUTINIB (AS MONOHYDRATE) ()
BOSUTINIB HYDRATE ()
BOSUTINIB MONOHYDRATE ()
SK-606 ()
Bosutinib ()
Bosutinib-d8 ()
SKI-606 (hydrate) ()
P&D ID
PD004099
CAS
380843-75-4
380443-75-4
918639-08-4
2733145-45-2
Tags
available
drug
Approved by
FDA
PMDA
First approval
2012
Drug indication
Breast cancer
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Food increase the exposure of bosutinib. ; Tmax, single dose, cancer patients, fed-state = 4-6 hours;; After 15 daily doses of bosutinib 500 mg with food in CML patients, the pharmacokinetic parameters are as follows:; Cmax = 200 ng/mL; ; AUC = 3650 ng∙h/mL;
DESCRIPTION Bosutinib is a Type-1 kinase inhibitor. This compound is a dual inhibitor of Src family kinases and Abl kinase activity . Bosutinib has been shown to stimulate macrophage clearance of bacterial infections . Although it does not have intrinsic antibacterial activity, bosutinib could be used to boost host innate immunity and delivered as part of an antibacterial drug combination for the treatment for drug-resistant bacterial infections . (GtoPdb)
DESCRIPTION Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients. (PKIDB)
DESCRIPTION Potent c-MET/ALK inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Dual Src-Abl inhibitor; antiproliferative (Tocriscreen Plus)
Cell lines
473
Organisms
2
Compound Sets
36
AdooQ Bioactive Compound Library
A10161
Axon Medchem Screening Library
1407
Cayman Chemical Bioactives
12030
25460
ChEMBL Approved Drugs
CHEMBL288441
CHEMBL2095206
ChEMBL Drugs
CHEMBL288441
CHEMBL2095206
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
5710
Concise Guide to Pharmacology 2019/20
5710
Concise Guide to Pharmacology 2021/22
5710
Concise Guide to Pharmacology 2023/24
5710
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB06616
DrugBank Approved Drugs
DB06616
DrugCentral
4359
DrugCentral Approved Drugs
4359
DrugMAP
DMTI8YE
DrugMAP Approved Drugs
DMTI8YE
EU-OPENSCREEN Bioactive Compound Library
EOS101765
Guide to Pharmacology
5710
LINCS compound set
10189-101
10189-999
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL288441
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL288441
MedChem Express Bioactive Compound Library
HY-10158
HY-10158A
NCATS Inxight Approved Drugs
5018V4AEZ0
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
Bosutinib
TargetMol Bioactive Compound Library
T0152
Tocris Bioactive Compound Library
4361
Tocriscreen Plus
4361
Welcome Trust Cancer Drugs
1019
ZINC Tool Compounds
ZINC000022448983
External IDs
51
Properties
(calculated by RDKit )
Molecular Weight
529.16
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
1
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
3
cLogP
5.19
TPSA
82.88
Fraction CSP3
0.38
Chiral centers
0.0
Largest ring
6.0
QED
0.38
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
SRC,ABL1
Target Type
Enzymes
Pathway
ABL signaling
Angiogenesis
Cytoskeletal Signaling
Tyrosine Kinase/Adaptors
Autophagy
Protein Tyrosine Kinase/RTK
Target
SRC, ABL, TEC
ABL
c-Src
ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK
Abl/Src inhibitor
SRC
BCR
ABL1
Lyn
Hck
CDK2
MAP2K1
MAP2K2
MAP3K2
CAMK2G
Autophagy,Bcr-Abl,ERK,S6 Kinase,Src,STAT
Primary Target
Src Kinases
MOA
Bcr-Abl
Src
Inhibitor
Abl Kinase Inhibitors
Apoptosis Inducers
Bcr-Abl Kinase Inhibitors
Inhibitors of Signal Transduction Pathways
Src Kinase Inhibitors
STAT-5 Inhibitors
Abl kinase inhibitor, Bcr-Abl kinase inhibitor, SRC inhibitor
Member status
virtual
Indication
chronic myeloid leukemia (CML)
Therapeutic Class
Anticancer Agents
Source data